ADCs have become a promising class of anti-tumor drugs, with over a dozen ADCs approved for treating various types of cancer patients. Traditional ADCs utilize the amino groups of antibody lysines or the thiol groups obtained from the reduction of inter-chain disulfide bonds in cysteines for coupling. However, their uniformity is poor, and stability is … Read more
Antibody-drug conjugates (ADC) mainly consist of three “modules”: an antibody (generally a monoclonal antibody), a linker, and a cytotoxic drug (Payload). In recent years, ADC drugs have stood out among biopharmaceuticals due to their combination of the potent killing effect of chemotherapy drugs and the precise targeting of antibody drugs, earning them the title of … Read more
Source: YaoDu Author: Cheng Chuan Yuan Hang Editor: Wan Zi 1 Introduction Antibody-Drug Conjugates (ADCs) are a novel class of highly effective biopharmaceuticals that link antibodies (Antibody) to biologically active small-molecule cytotoxic payloads (Payload) via linkers (Linker). ADCs aim to enhance the therapeutic index (TI) of chemotherapeutic agents by more selectively delivering cytotoxic drugs to … Read more
1. Overview Antibody-drug conjugates (ADCs) rejuvenate the concept of targeted chemotherapy by coupling cytotoxic payloads to antibodies. The first stage of the complex intracellular toxin delivery process of ADCs is endocytosis. Analyzing the endocytic action of target receptors and ADCs can greatly advance preclinical research, clinical translation, and patient treatment outcomes. The in vitro efficacy … Read more
Previous Reviews 2023 Overview of Antibody Drug Industry Development History of Monoclonal Antibodies, This Article is Enough! Brief Discussion on the Mechanism of Action and Advantages/Disadvantages of Antibodies How to Name Monoclonal Antibodies, Read This! Magic Bullet – ADC Antibody-drug conjugates (ADC) are a class of targeted biological agents composed of an antibody, a linker, … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens to small-molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small-molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute myeloid leukemia, dozens … Read more
Chemotherapy, as one of the main options for cancer treatment, has limited selectivity for cancer cells, a narrow therapeutic window, and potential high toxicity, which restricts its clinical application. Antibody-drug conjugates (ADCs), as emerging anticancer therapeutics, can deliver highly cytotoxic molecules directly to cancer cells to exert their lethal effects. ADCs are formed by the … Read more
From “Magic Bullets” to the Birth of ADC Drugs As early as 1913, Paul Ehrlich first proposed the concept of “magic bullets” and drug targeting. However, it wasn’t until the rapid development of antibody technology in the 1970s that the first antibody-drug conjugate (ADC) — Gemtuzumab ozogamicin (GO), targeting CD33, was approved by the FDA … Read more
▉ Introduction Antibody-drug conjugates (ADCs) are composed of monoclonal antibodies that specifically target antigens linked to small molecule cytotoxic drugs via linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor-targeting capability of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, … Read more
–01– Introduction For decades, advancements in antibody-drug conjugates (ADC) and bioconjugates have revolutionized targeted therapies for various diseases. Unlike traditional chemotherapy, ADCs selectively target tumor cells while sparing normal cells, making them highly suitable for cancer treatment. Currently, there are 17 types of ADCs approved by regulatory agencies in different countries worldwide. Over 200 more … Read more